Amphastar Pharmaceuticals (AMPH) Competitors $21.21 +0.26 (+1.24%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$21.38 +0.18 (+0.83%) As of 08/1/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AMPH vs. ZLAB, AKRO, ACLX, ACAD, VKTX, SRRK, PTCT, SWTX, MLTX, and PTGXShould you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include Zai Lab (ZLAB), Akero Therapeutics (AKRO), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), Scholar Rock (SRRK), PTC Therapeutics (PTCT), SpringWorks Therapeutics (SWTX), MoonLake Immunotherapeutics (MLTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Amphastar Pharmaceuticals vs. Its Competitors Zai Lab Akero Therapeutics Arcellx ACADIA Pharmaceuticals Viking Therapeutics Scholar Rock PTC Therapeutics SpringWorks Therapeutics MoonLake Immunotherapeutics Protagonist Therapeutics Zai Lab (NASDAQ:ZLAB) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings. Does the media refer more to ZLAB or AMPH? In the previous week, Zai Lab had 1 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 10 mentions for Zai Lab and 9 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.87 beat Zai Lab's score of 0.72 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amphastar Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ZLAB or AMPH more profitable? Amphastar Pharmaceuticals has a net margin of 19.38% compared to Zai Lab's net margin of -60.26%. Amphastar Pharmaceuticals' return on equity of 22.20% beat Zai Lab's return on equity.Company Net Margins Return on Equity Return on Assets Zai Lab-60.26% -33.35% -23.28% Amphastar Pharmaceuticals 19.38%22.20%10.40% Do analysts recommend ZLAB or AMPH? Zai Lab currently has a consensus target price of $54.28, indicating a potential upside of 47.41%. Amphastar Pharmaceuticals has a consensus target price of $32.33, indicating a potential upside of 52.44%. Given Amphastar Pharmaceuticals' higher possible upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than Zai Lab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zai Lab 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Amphastar Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Do insiders and institutionals believe in ZLAB or AMPH? 41.7% of Zai Lab shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 5.0% of Zai Lab shares are held by insiders. Comparatively, 27.5% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation and earnings, ZLAB or AMPH? Amphastar Pharmaceuticals has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZai Lab$398.99M10.25-$257.10M-$2.49-14.79Amphastar Pharmaceuticals$731.97M1.37$159.52M$2.767.68 Which has more volatility & risk, ZLAB or AMPH? Zai Lab has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. SummaryAmphastar Pharmaceuticals beats Zai Lab on 11 of the 16 factors compared between the two stocks. Get Amphastar Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMPH vs. The Competition Export to ExcelMetricAmphastar PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$987.56M$3.75B$5.47B$9.53BDividend YieldN/A1.17%4.74%4.08%P/E Ratio7.689.2028.6723.80Price / Sales1.3711.89422.3188.12Price / Cash4.196.3535.4557.96Price / Book1.392.658.275.55Net Income$159.52M-$109.62M$3.24B$259.03M7 Day Performance-5.19%-1.94%-3.63%-4.56%1 Month Performance-10.05%8.51%4.40%4.49%1 Year Performance-48.98%24.02%25.97%18.05% Amphastar Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPHAmphastar Pharmaceuticals4.377 of 5 stars$21.21+1.2%$32.33+52.4%-50.0%$987.56M$731.97M7.682,028News CoverageUpcoming EarningsZLABZai Lab2.1983 of 5 stars$38.69+4.1%$54.28+40.3%+99.7%$4.13B$398.99M-15.541,869News CoveragePositive NewsUpcoming EarningsShort Interest ↑Gap UpAKROAkero Therapeutics3.9446 of 5 stars$49.24-2.6%$82.50+67.5%+83.6%$4.03BN/A-25.2530Positive NewsUpcoming EarningsACLXArcellx2.5739 of 5 stars$70.59-1.0%$111.23+57.6%+21.3%$3.93B$107.94M-23.6180News CoveragePositive NewsAnalyst ForecastACADACADIA Pharmaceuticals3.988 of 5 stars$22.62-2.7%$28.13+24.3%+23.9%$3.89B$957.80M16.51510News CoverageUpcoming EarningsAnalyst RevisionVKTXViking Therapeutics3.7591 of 5 stars$33.20-3.5%$86.92+161.8%-40.2%$3.87BN/A-21.7020Short Interest ↑SRRKScholar Rock3.7908 of 5 stars$37.09-4.8%$42.67+15.0%+301.3%$3.70B$33.19M-14.66140News CoveragePositive NewsUpcoming EarningsAnalyst ForecastPTCTPTC Therapeutics4.4809 of 5 stars$44.36-0.9%$65.77+48.3%+59.5%$3.55B$806.78M6.811,410Trending NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionSWTXSpringWorks TherapeuticsN/A$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230Upcoming EarningsMLTXMoonLake Immunotherapeutics2.7013 of 5 stars$54.47-1.1%$73.14+34.3%+25.9%$3.53BN/A-23.682News CoverageUpcoming EarningsPTGXProtagonist Therapeutics2.1166 of 5 stars$56.26+2.0%$66.10+17.5%+41.8%$3.42B$434.43M75.01120Positive NewsUpcoming Earnings Related Companies and Tools Related Companies ZLAB Competitors AKRO Competitors ACLX Competitors ACAD Competitors VKTX Competitors SRRK Competitors PTCT Competitors SWTX Competitors MLTX Competitors PTGX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMPH) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amphastar Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
